Outcomes in Patients With Aggressive or Refractory Disease From REVEL, a Randomized Phase III Study of Docetaxel With Ramucirumab or Placebo for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer

Lung Cancer - Netherlands
doi 10.1016/j.lungcan.2017.07.038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2016English

A Phase II Trial of Docetaxel and Ifosfamide for Patients With Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

Cancer Research and Treatment
Cancer ResearchOncology
2004English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Phase II Study of Ramucirumab and Docetaxel for Previously Treated Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion: Protocol of PLEURAM Study

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Phase III Study of Cisplatin With Pemtrexed or Vinorelbine Plus Concurrent Late Course Accelerated Hyperfractionated Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Lipegfilgrastim in Patients With Non-Small Cell Lung Cancer Receiving Myelosuppressive Therapy

SpringerPlus
Multidisciplinary
2015English

Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy